Full Logo - OKYO .jpg
OKYO Pharma Announces Chairman Acquires Shares
September 10, 2024 07:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
September 10, 2024 07:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
poet-logo@2018.png
POET Selected by Mentech to Supply Engines for 800G and 1.6T Optical Modules
September 10, 2024 07:00 ET | POET Technologies Inc.
TORONTO and SHENZHEN, China, Sept. 10, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical...
Tonix2.jpg
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations
September 10, 2024 07:00 ET | Tonix Pharmaceuticals Holding Corp.
Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on track to submit an NDA for TNX-102 SL for fibromyalgia in October of...
ACELYRIN, INC. Logo.jpg
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
September 10, 2024 07:00 ET | ACELYRIN, INC.
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical...
logo.png
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
September 10, 2024 07:00 ET | Centessa Pharmaceuticals plc
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations...
Virtu Logo Horiz Color Navy Txt RGB.png
Virtu Financial Announces Direct Connectivity of Triton Valor EMS to Tokyo Stock Exchange’s CONNEQTOR
September 10, 2024 07:00 ET | Virtu Financial, LLC
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent...
Mural_Logo.jpg
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024 07:00 ET | Mural Oncology, Inc.
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
Aclaris_Logo_CLR®.jpg
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET | Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
ADMA_Biologics_RGB L -092115P.jpg
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET | ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...